Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
Dr. Appel to discuss the potential of combination immunotherapy in ALS ...
Source: marketscreener.com
Howardh Berman News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Howardh Berman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Howardh Berman Today - Breaking & Trending Today
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson's Disease in Addition to Amyotrophic Lateral Sclerosis -January 16, 2024 at 08:16 am EST
All three conditions share common hallmark of complex inflammatory pathways underlying disease pathophysiology that involve dysfunctional regulatory T cell biology which may limit efficacy of...
Source: marketscreener.com
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Coya has a clear path towards submission of the IND application to the FDA in the second quarter of 2024, with a planned initiation of a well-controlled, double-blind clinical trial of COYA 302 in...
Source: marketscreener.com
Coya Therapeutics ("Coya") Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
Dr. Grossman brings over 20 years of drug development expertise having held senior executive leadership positions in large and small pharmaceutical companies leading the development and FDA approval of numerous multi-billion dollar blockbuster drugs addressing significant unmet medical needs particularly across CNS disorders. Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He served as President and Chief Medical Officer at Glenmark Pharmaceuticals (BSE: 532296) as well as Chief Medical Officer at Mesoblast, Inc. (NASDAQ: MESO). Dr...
Source: marketscreener.com
Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs
Dr. Frazier brings over 20 years of strong regulatory expertise since her tenure at the FDA followed by a successful career in the pharmaceutical industry. Dr. Frazier spent 7 years at the FDA,... | June 14, 2023
Source: marketscreener.com